NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of clinical data for its lead drug candidate, selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound, during a Karyopharm-sponsored event with webcast scheduled for Monday, December 7, 2015 from 8:30 - 9:30 p.m. ET, immediately following formal programming for the 57th American Society of Hematology (ASH) Annual Meeting. The event, entitled "Broadening the Foundation for SINE-Based Therapy in Oncology: ASH 2015," will include presentations by selinexor clinical investigators and Karyopharm management describing new clinical data, including data related to selinexor's activity in combination with other active agents in multiple myeloma and acute myeloid leukemia, followed by a Q&A session.
A live webcast of the presentation will begin at 8:30 p.m. ET and can be accessed under "Events & Presentations" in the Investors section of the company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the company's website for 90 days following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). SINE™ compounds have also shown biological activity in models of cancer, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.